ZYUS Life Sciences has collaborated with University of Saskatchewan’s Vaccine and Infectious Disease Organisation-International Vaccine Centre (VIDO-InterVac) for the development of a plant-based vaccine for Covid-19 disease.
The partnership will focus on the testing of a plant produced antigens in a vaccine for Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus
VIDO-InterVac director Dr Volker Gerdts said: “Through this partnership, we are exploring alternative methods of antigen production with a goal to potentially expand global vaccine production capacity for Covid-19.”
ZYUS will leverage its bio-pharmaceutical plant technology platform, as well as its expertise for the development and expression of a protein, which VIDO-InterVac has detected as a potential antigen for a Covid-19 vaccine.
ZYUS will isolate the protein in its plant expression system and offer insights into whether plants can generate antigens, which are suitable for use in a Covid-19 vaccine.
The company aims to extract enough specific protein through its plant expressions system for VIDO-InterVac by mid-summer this year to evaluate its effectiveness in animal models of Covid-19 disease.
VIDO-InterVac claimed that the current approach is one of several programmes to expand vaccine development against the novel coronavirus.
ZYUS Life Sciences CEO Brent Zettl said: “Developing vaccines in plant cells has multiple potential benefits, including the ability to quickly produce a vaccine at scale, having no animal pathogen contaminants, and lower bioreactor processing costs.
“This is an important initiative for us as an organization, and as citizens looking to make a difference, ZYUS is committing research and development expertise, resources and energy to help find a vaccine now and to develop systems to help respond in the future.”
Junshi’s JS016 is a recombinant fully human monoclonal neutralising antibody, which is specific to the SARS-CoV-2 surface spike protein receptor-binding domain.